August 13, 2021 07:18 AM EDT
R&D
FDA+

Ipsen with­draws NDA for rare bone dis­ease treat­ment less than 3 months af­ter win­ning pri­or­i­ty re­view

Max Gelman

Senior Editor

Af­ter win­ning pri­or­i­ty re­view for its ul­tra-rare bone dis­ease pro­gram at the end of May, Ipsen made an abrupt about-face Fri­day.

Ipsen with­drew its NDA …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Trump team asked Warp Speed leader to head NIH, may seek more tra­di­tion­al pick for role

Bris­tol My­ers re­veals more job cuts in New Jer­sey

How did Trump’s FDA pick land? Biotech stocks are up, and ex­ec­u­tives are (most­ly) re­lieved

Mer­ck halts Phase 3 tri­al with PAH drug Win­re­vair fol­low­ing pos­i­tive in­ter­im da­ta 

In­cyte touts Mon­ju­vi da­ta from Phase 3 fol­lic­u­lar lym­phoma tri­al as it heads to FDA

Min­neso­ta 340B rev­enue dri­ven by hos­pi­tals and high-priced drugs, first state re­port says

A service from the Financial Times